Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Smoldering and Chronic Adult T-cell Leukemia (ATL)
NCT01712659Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2012
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in adult T-cell leukemia/lymphoma (ATLL), sponsored by National Cancer Institute. Started Oct 2012; status: terminated.
02
Drugs
03
Conditions
adult T-cell leukemia/lymphoma (ATLL)
Beyond the preview
Go deeper on NCT01712659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712659.